ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 69 citations in OpenAlex.
- SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression.Cancer research communications · 2025Article
- SEL1L confers reduced EMT and drug resistance to breast cancer cells by promoting Shh degradation.iScience · 2025Article
- Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.British journal of cancer · 2025Article
- Gut-Vaginal Microbiome Crosstalk in Ovarian Cancer: Implications for Early Diagnosis.Pathogens (Basel, Switzerland) · 2025Review
- Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology.Journal of translational medicine · 2025Review
- Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.Molecular therapy. Oncology · 2024Article
- Advances in ovarian tumor stem cells and therapy.Cell biochemistry and biophysics · 2024Review
- HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway.Cell death & disease · 2023Article
- Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.International journal of molecular sciences · 2023Review
- Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis.Redox biology · 2023Article
- Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling.Biomedicines · 2023Article
- Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence.Cancer metastasis reviews · 2023Review
- BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression.Experimental & molecular medicine · 2023Article
- BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer.Cancers · 2023Article
- "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.Frontiers in oncology · 2023Review
- Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.PloS one · 2023Article
- Small molecule inhibitors targeting the cancers.MedComm · 2022Review
- Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer.International journal of molecular sciences · 2022Article
- RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation.iScience · 2022Article
- Cross-Talk between Wnt Signaling and Src Tyrosine Kinase.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Fiona SimpkinsBraman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. jslingerland@med.miami.edu Fiona.simpkins@uphs.upenn.edu.
Kibeom Jang *Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Hyunho Yoon *Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Karina E Hew *Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Minsoon KimBraman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Diana J AzzamBraman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Jun SunBraman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Dekuang ZhaoBraman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Tan A InceBraman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Wenbin LiuDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wei GuoDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhi WeiDepartment of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.
Gao ZhangWistar Institute, Philadelphia, Pennsylvania.
Gordon B MillsDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Joyce M SlingerlandBraman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. jslingerland@med.miami.edu Fiona.simpkins@uphs.upenn.edu.
University of Miami · USSylvester Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USNew Jersey Institute of Technology · USThe Wistar Institute · US
Funding
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YUAN, YING · 2017 to 2021
$7.9MBiological annotation of TCGA dataU01CA168394 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2012 to 2016
$4.7MIntegrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6MTargeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian CancerK08CA151892 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SIMPKINS, FIONA · 2011 to 2016
$807kNCI NIH HHS K08 CA151892NCI NIH HHS P50 CA217685NCI NIH HHS U01 CA168394NCI NIH HHS U01 CA217842
Abstract
PubMed holds no abstract for this paper.
Indexed as
ProteomicsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBenzimidazolesBenzodioxolesCell Line, TumorCell ProliferationDisease-Free SurvivalDrug Resistance, NeoplasmEstrogen Receptor alphaFemaleHumansMAP Kinase Kinase 1MiceMiddle AgedAZD 6244BenzimidazolesBenzodioxolesEstrogen Receptor alphaMAP Kinase Kinase 1Protein Kinase InhibitorsQuinazolinessaracatinibsrc-Family Kinases
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.